State of HIV costing in Latin America and the Caribbean
A systematic literature review
Bibliographic Data
| ID | 14967526 |
|---|---|
| Authors | Diego Cerecero-Garcia (0000-0001-5368-9241, Public Health Policy Evaluation Unit, Imperial College, London, England.), Fern Terris-Prestholt (0000-0003-1693-5196, United Nations Joint Programme on HIV/AIDS, Geneva, Switzerland.), Fernando Macías-González (0000-0002-4731-3384, Center for Evaluation Research and Surveys, National Institute of Public Health, Mexico City, Mexico.), Sergio Bautista-Arredondo (0000-0001-8910-3011, Center for Evaluation Research and Surveys, National Institute of Public Health, Mexico City, Mexico.) |
| Year | 2024 |
| Volume | 48 |
| Pages | 1 |
| Publication date | 2024-09-16 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Revista Panamericana de Salud Pública (JOURNAL) |
| Journal identifiers | ISSN: 1020-4989 • E-ISSN: 1680-5348 |
| Publisher | Pan American Health Organization (PUBLISHER • US) |
| DOI | 10.26633/rpsp.2024.84 |
| Language | EN |
| Citations received | 2 |
| References cited | 20 |
Objectives. To summarize available data on unit costs for human immunodeficiency virus (HIV) testing, prevention, and care interventions in Latin America and the Caribbean. Methods. We conducted a systematic literature review of costing studies published between 2012 and 2024, and selected those reporting empirically measured costing data. The available data were categorized according to predefined intervention categories and compared by time and place. We also explored variations in unit costs by intervention type. Results. Of 1 746 studies identified, 22 met the inclusion criteria, which provided 103 unique unit cost estimates from nine countries. About 50% of the included studies were published between 2019 and 2021. Antiretroviral therapy services had the most cost data available (39% of unit costs), followed by inpatient care (27%) and HIV testing (24%). Considerable cost variations were observed both within and between interventions. Conclusions. Our analysis underscores the need for accurate and reliable cost data to support HIV budgeting and decision-making efforts. We identified several gaps in the availability of cost data and emphasize the importance of presenting results more effectively by incorporating key contextual variables. Given the challenges of shrinking budgets and sustainability risks, robust evidence is indispensable to inform priority setting and budget allocation for HIV services
Developing the Global Health Cost Consortium Unit Cost Study Repository for HIV and TB
The past, present and future of HIV, Aids and resource allocation
Lives Saved Tool (LiST) costing
The real and the nominal? Making inflationary adjustments to cost and other economic data
Out-of-pocket expenditures for HIV in the Dominican Republic
| Citations per year | 2 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |